Atossa Therapeutics, Inc. ATOS · Stock Open Atossa Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Atossa Therapeutics, Inc. Analysis (ATOS)
Is Atossa Therapeutics, Inc. a good investment? Atossa Therapeutics, Inc. (ATOS) is currently trading at 2.12 USD. Market analysts have a consensus price target of 19.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Atossa Therapeutics, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -3.30.
Investor FAQ
Does Atossa Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Atossa Therapeutics, Inc.?
Atossa Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -4.45.
Company Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 26, 2016 | 1:15 |
| April 20, 2018 | 1:12 |
| Feb. 2, 2026 | 1:15 |
Community Discussion